earnings
confidence high
sentiment positive
materiality 0.75
Medtronic Q1 FY25: revenue $7.9B (+2.8%), GAAP EPS $0.80, non-GAAP EPS $1.23; raises FY25 guidance
Medtronic plc
2025-Q1 EPS reported
$0.80
revenue$7,915,000,000
- Revenue $7.915B (adjusted $8.004B), up 5.3% organic; GAAP EPS $0.80, non-GAAP EPS $1.23 (+8% constant currency).
- Raises FY25 organic revenue growth guidance to 4.5%-5% (from 4-5%) and non-GAAP EPS guidance to $5.42-$5.50.
- Cardiovascular $3.007B (+6.9% organic) driven by CRM and PFA; Neuroscience $2.317B (+5.3% organic) with Neuromodulation up low-double digits.
- Diabetes $647M (+12.6% organic) on MiniMed 780G; Simplera CGM FDA approved, Abbott partnership for future integrated CGM.
- Medical Surgical $1.996B (+1.0% organic) with SE low-single digit growth and ACM flat.